Adlai Nortye Ltd. (NASDAQ:ANL) Short Interest Up 21.5% in June

Adlai Nortye Ltd. (NASDAQ:ANL) was the recipient of a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 13,000 shares, an increase of 21.5% from the May 31st total of 10,700 shares. Based on an average daily volume of 16,500 shares, the days-to-cover ratio is currently 0.8 days.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Adlai Nortye in a research note on Thursday, June 20th.

Adlai Nortye Stock Performance

ANL stock opened at $3.26 on Monday. Adlai Nortye has a 1-year low of $3.04 and a 1-year high of $19.30. The company’s 50 day moving average is $9.05 and its 200 day moving average is $8.97.

Hedge Funds Weigh In On Adlai Nortye

An institutional investor recently raised its position in Adlai Nortye stock. Cantor Fitzgerald L. P. boosted its position in Adlai Nortye Ltd. (NASDAQ:ANL) by 128.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 40,310 shares of the company’s stock after acquiring an additional 22,644 shares during the quarter. Cantor Fitzgerald L. P. owned 0.11% of Adlai Nortye worth $362,000 as of its most recent filing with the Securities & Exchange Commission. 35.21% of the stock is currently owned by institutional investors and hedge funds.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.